Completed PHASE2 INTERVENTIONAL 1-arm
NCT06903910
Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease
Sponsor: University of Virginia
Conditions
Parkinson Disease
Interventions
Donepezil (Aricept)
Updated 2 times since 2025 Last updated: Mar 6, 2026 Started: Nov 1, 2024 Primary completion: Jun 30, 2025 Completion: Jan 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Parkinson Disease, this trial is completed. The trial is conducted by University of Virginia and has accumulated 2 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Mar 2026 — Present [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
May 2025 — Mar 2026 [monthly]
Recruiting PHASE2
First recorded
Nov 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- University of Virginia
Data source: University of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .